The Use of NT-proBNP and BNP as Biomarkers of Acute Heart Failure
The Use of NT-proBNP and BNP as Biomarkers of Acute Heart Failure
The Use of NT-proBNP and BNP as Biomarkers of Acute Heart Failure
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Study Endpoints<br />
•1 endpoint<br />
•Total cardiov<strong>as</strong>cular<br />
events*<br />
• Worsening HF †<br />
• HF hospitalization<br />
• ACS<br />
• Ventricular arrhythmia<br />
• Cerebral ischemia<br />
• Cardiov<strong>as</strong>cular death<br />
•2 endpoints<br />
•Quality <strong>of</strong> life<br />
•Changes in echo<br />
parameters<br />
• LV ejection fraction<br />
• LVESVi<br />
• LVEDVi<br />
*Assessed using generalized estimating equations<br />
†<br />
Requiring at le<strong>as</strong>t 2 from the following: symptoms <strong>of</strong> congestion or falling cardiac output,<br />
signs <strong>of</strong> new congestion on exam, use <strong>of</strong> “bail out” decongestive therapy, or rising <strong>NT</strong>-<strong>pro<strong>BNP</strong></strong><br />
in the un-blinded arm<br />
Source: Januzzi et al. clinicaltrialresults.org/Slides/PROTECT%20Presentation%20FINAL.ppt, accessed March 27, 2012<br />
27
Change language